Chlorzoxazone
Chlorzoxazone (chlorzoxazone) is a small molecule pharmaceutical. Chlorzoxazone was first approved as Paraflex on 1982-01-01. It is used to treat muscle cramp, muscle rigidity, myositis, pain, and spasm in the USA. It is known to target intermediate conductance calcium-activated potassium channel protein 4 and small conductance calcium-activated potassium channel protein 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Chlorzoxazone (discontinued: Chlorzoxazone, Paraflex, Parafon, Strifon)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Chlorzoxazone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PARAFON FORTE DSC | Johnson & Johnson | N-011529 DISCN | 1987-06-15 | 1 products, RLD |
| PARAFLEX | Johnson & Johnson | N-011300 DISCN | 1982-01-01 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| chlorzoxazone | ANDA | 2024-10-08 |
| lorzone | ANDA | 2023-09-29 |
| parafon dsc | ANDA | 2010-02-09 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| myositis | EFO_0000783 | D009220 | G72.49 |
| pain | EFO_0003843 | D010146 | R52 |
| muscle cramp | HP_0003394 | D009120 | — |
| spasm | — | D013035 | M62.83 |
| muscle rigidity | HP_0002063 | D009127 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
— M03: Muscle relaxants
— M03B: Muscle relaxants, centrally acting agents
— M03BB: Oxazol, thiazine, and triazine derivatives centrally acting muscle relaxants
— M03BB03: Chlorzoxazone
— M03BB53: Chlorzoxazone, combinations excl. psycholeptics
— M03BB73: Chlorzoxazone, combinations with psycholeptics
HCPCS
No data
Clinical
Clinical Trials
9 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 1 | — | 1 |
| Postoperative pain | D010149 | — | G89.18 | — | — | — | 1 | — | 1 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | — | 1 | — | 1 |
| Hip osteoarthritis | D015207 | EFO_1000786 | M16 | — | — | — | 1 | — | 1 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | 1 | — | 1 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
| Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Morbid obesity | D009767 | EFO_0001074 | — | — | — | — | — | 1 | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
| Bariatric surgery | D050110 | — | — | — | — | — | — | 1 | 1 |
| Depression | D003863 | — | F33.9 | — | — | — | — | 1 | 1 |
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | — | — | — | 1 | 1 |
| Smoking cessation | D016540 | EFO_0004319 | — | — | — | — | — | 1 | 1 |
| Alcohol drinking | D000428 | EFO_0004329 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Chlorzoxazone |
| INN | chlorzoxazone |
| Description | Chlorzoxazone is a member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm. It has a role as a muscle relaxant and a sedative. It is a member of 1,3-benzoxazoles, an organochlorine compound and a heteroaryl hydroxy compound. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=c1[nH]c2cc(Cl)ccc2o1 |
Identifiers
| PDB | — |
| CAS-ID | 95-25-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1371 |
| ChEBI ID | 3655 |
| PubChem CID | 2733 |
| DrugBank | DB00356 |
| UNII ID | H0DE420U8G (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
KCNN2
KCNN2
Organism
Homo sapiens
Gene name
KCNN2
Gene synonyms
NCBI Gene ID
Protein name
small conductance calcium-activated potassium channel protein 2
Protein synonyms
apamin-sensitive small-conductance Ca2+-activated potassium channel, KCa2.2, potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 2, potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2, small conductance calcium-activated potassium channel 2
Uniprot ID
Mouse ortholog
Kcnn2 (140492)
small conductance calcium-activated potassium channel protein 2 (P58390)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Chlorzoxazone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,558 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
556 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use